title: RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
authors.affiliation: Roche Palo Alto LLC, Palo Alto, California, USA.
authors.forename: Sophie
authors.initials: S
authors.lastname: Le Pogam
authors.forename: Amritha
authors.initials: A
authors.lastname: Seshaadri
authors.forename: Aren
authors.initials: A
authors.lastname: Ewing
authors.forename: Hyunsoon
authors.initials: H
authors.lastname: Kang
authors.forename: Alan
authors.initials: A
authors.lastname: Kosaka
authors.forename: Jun-Mei
authors.initials: JM
authors.lastname: Yan
authors.forename: Michelle
authors.initials: M
authors.lastname: Berrey
authors.forename: Bill
authors.initials: B
authors.lastname: Symonds
authors.forename: Abel
authors.initials: A
authors.lastname: De La Rosa
authors.forename: Nick
authors.initials: N
authors.lastname: Cammack
authors.forename: Isabel
authors.initials: I
authors.lastname: Nájera